aTyr Pharma Inc
ATYR0.827USD
-0.054-6.14%
收盘 11/04, 16:00（美东）报价延迟15分钟
76.77M总市值
亏损市盈率 TTM
关于 aTyr Pharma Inc 公司
aTyr Pharma, Inc. 是一家临床阶段的生物技术公司。该公司正在利用情报将 tRNA 合成酶生物学转化为治疗纤维化和炎症的新疗法。其主要治疗候选药物是 efzofitimod，这是一种生物免疫调节剂，处于临床开发阶段，用于治疗间质性肺病 (ILD)，这是一组可导致肺部炎症和纤维化或瘢痕形成的免疫介导疾病。Efzofitimod 是一种 tRNA 合成酶衍生疗法，可通过神经纤毛蛋白-2 (NRP2) 选择性调节活化的髓系细胞，以在不抑制免疫的情况下解决异常炎症并防止纤维化进展。ATYR0101 是一种源自天冬氨酰-tRNA 合成酶 (DARS) 结构域的融合蛋白。ATYR0101 直接与潜伏转化生长因子 β 结合蛋白 1 (LTBP1) 结合，后者调节转化生长因子 β (TGFb)。其 ATYR0750 是一种源自丙氨酰-tRNA 合成酶 (AARS) 结构域的融合蛋白。
aTyr Pharma Inc简介
公司代码ATYR
公司名称aTyr Pharma Inc
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
员工数量56
证券类型Ordinary Share
年结日May 07
公司地址10240 Sorrento Valley Road
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18587318389
网址https://www.atyrpharma.com/
公司代码ATYR
上市日期May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
aTyr Pharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Sara A. Zaknoen, M.D.
Dr. Sara A. Zaknoen, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月2日 周日
更新时间: 11月2日 周日
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.63%
Federated Hermes Global Investment Management Corp.
10.76%
BlackRock Institutional Trust Company, N.A.
5.45%
The Vanguard Group, Inc.
4.75%
Octagon Capital Advisors LP
3.90%
其他
61.51%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.63%
Federated Hermes Global Investment Management Corp.
10.76%
BlackRock Institutional Trust Company, N.A.
5.45%
The Vanguard Group, Inc.
4.75%
Octagon Capital Advisors LP
3.90%
其他
61.51%
股东类型
持股股东
占比
Investment Advisor
29.62%
Investment Advisor/Hedge Fund
17.36%
Hedge Fund
15.90%
Individual Investor
1.43%
Research Firm
1.03%
Bank and Trust
0.11%
Pension Fund
0.10%
Insurance Company
0.03%
其他
34.42%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
214
63.66M
64.97%
-3.77M
2025Q2
165
66.71M
74.73%
+3.74M
2025Q1
162
64.83M
72.99%
-691.51K
2024Q4
140
57.60M
68.66%
-6.81M
2024Q3
117
50.41M
67.53%
-11.03M
2024Q2
113
50.68M
74.24%
-3.06M
2024Q1
111
44.35M
66.05%
-8.23M
2023Q4
110
43.49M
75.20%
-5.05M
2023Q3
109
43.22M
76.15%
+288.84K
2023Q2
108
41.84M
78.83%
+2.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
13.35M
13.63%
+457.14K
+3.55%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
14.67M
14.97%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.34M
5.45%
+3.83M
+253.28%
Jun 30, 2025
The Vanguard Group, Inc.
4.66M
4.75%
+648.31K
+16.18%
Jun 30, 2025
Octagon Capital Advisors LP
3.82M
3.9%
+268.00K
+7.55%
Jun 30, 2025
Tikvah Management LLC
2.46M
2.51%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
2.10M
2.14%
+1.17M
+126.13%
Jun 30, 2025
UBS Financial Services, Inc.
1.75M
1.78%
+138.23K
+8.60%
Jun 30, 2025
Woodline Partners LP
1.68M
1.72%
--
--
Jun 30, 2025
Millennium Management LLC
1.60M
1.63%
+1.16K
+0.07%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Vanguard US Momentum Factor ETF
0.05%
SPDR S&P Biotech ETF
0.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.02%
iShares Micro-Cap ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Global X Russell 2000 ETF
0%
查看更多
Vanguard US Momentum Factor ETF
占比0.05%
SPDR S&P Biotech ETF
占比0.03%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.02%
iShares Micro-Cap ETF
占比0.01%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Growth ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
Global X Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
